Laruparetigene zovaparvovec is under clinical development by Beacon Therapeutics and currently in Phase III for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase III drugs for Retinitis Pigmentosa (Retinitis) have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Laruparetigene zovaparvovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Laruparetigene zovaparvovec overview

Laruparetigene zovaparvovec (AGTC-501) is under development for the treatment of X-linked retinitis pigmentosa (XLRP). It is administered through subretinal injection and acts by targeting X-linked retinitis pigmentosa GTPase regulator (RPGR). The gene therapy is developed based on adeno-associated virus (AAV) vector technology platform.

Beacon Therapeutics overview

Beacon Therapeutics is a biotechnology research company which focuses on ophthalmic gene therapy to improve vision of patients with rare retinal diseases that cause blindness. The company is headquartered in London, Greater London, the UK.

For a complete picture of Laruparetigene zovaparvovec’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.